Table 1.
Tracer(s) | Patient number |
Disease stage | Study objective |
Sensitivity | Specificity | Year | Group |
---|---|---|---|---|---|---|---|
18F-FDG | 48 | Early | Staging | 81% | NA | 1996 | Effert PJ, et al. |
18F-FDG | 13 | Advanced | Staging | NA | NA | 1996 | Yeh SD, et al. |
18F-FDG | 34 | Advanced | Staging | 65% | NA | 1996 | Shreve PD, et al |
18F-FDG | 18 | Mixed | Restaging | NA | NA | 1999 | Hofer C, et al |
18F-FDG | 44 | Early | Staging | 64% | NA | 1999 | Oyama N, et al. |
18F-FDG | 24 | Early | Staging | 4% | NA | 2001 | Liu IJ, et al. |
18F-FDG | 10 | Advanced | Restaging | NA | NA | 2001 | Oyama N, et al. |
18F-FDG | 42 | Early | Staging | NA | NA | 2002 | Oyama N, et al. |
18F-FDG | 17 | Advanced | Staging | NA | NA | 2002 | Morris MJ, et al. |
18F-FDG | 24 | Advanced | Re-staging | 75% | 100% | 2003 | Chang CH, et al. |
18F-FDG | 91 | Mixed | Restaging | 31% | NA | 2005 | Schoder H, et al |
18F-FDG, 11C-methionine | 10 | Advanced | Staging | NA | NA | 1999 | Mascapinlac HA, et al |
18F-FDG, 11C-methionine | 12 | Advanced | Staging | 48% (72%) | NA | 2002 | Nunez R, et al. |
18F-FDG, 11C-acetate | 15 (25) | Mixed | Staging | NA | NA | 2003 | Fricke E, et al |
18F-FDG, 11C-acetate | 18(22) | Early | Staging | NA | NA | 2002 | Oyama N, et al. |
18F-FDG, 11C-acetate | 46 | Advanced | Restaging | NA | NA | 2003 | Oyama N, et al. |
18F-FDG, 11C-choline | 100 | Advanced | Restaging | 27% (47%) | NA | 2003 | Picchio M, et |
18F-FDG, 18F-FDHT | 7 | Advanced | Staging | 97% (78%) | NA | 2004 | Larson SM, et al. |
18F-FDG, 11C-choline, | 26 | Early | Staging | 73% | 59% | 2010 | Watanabe H, et al. |